PRISM

PRISM MarketView Features Auto Parts 4 Less in the Automotive E-Commerce Marketplace

Retrieved on: 
Friday, April 5, 2024
E-commerce, PRISM, O'Reilly Auto Parts, Interview

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Auto Parts 4 Less CEO Christopher Davenport, explaining the company’s strategic business model and focus on expanding its automotive eCommerce marketplace.

Key Points: 
  • NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Auto Parts 4 Less CEO Christopher Davenport, explaining the company’s strategic business model and focus on expanding its automotive eCommerce marketplace.
  • Auto Parts 4 Less is an innovator focused on developing a world-class eCommerce marketplace for automotive parts that utilizes integrated technologies to optimize the listing, selling, and shipping of these parts.
  • Davenport states, “Our vision from the start was to create a double-sided marketplace that added immense value to both sellers and buyers.
  • The full interview can be found at: https://prismmarketview.com/autoparts4less-closing-the-circuit-on-the-au...

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

Retrieved on: 
Monday, March 18, 2024
MASH, Name, PRISM, Patient, Non-alcoholic fatty liver disease, Therapy, Liver disease, Pharmaceutical industry

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™, and the companies leading the charge in developing new, safe and effective treatments for liver disease.

Key Points: 
  • NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™, and the companies leading the charge in developing new, safe and effective treatments for liver disease.
  • The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease, a leading cause of liver-related mortality that affects between six and eight million adults in the US.
  • Experts believe this overhaul may be the rebrand that liver disease needs to generate better clinical results for specific patient populations.
  • PRISM MarketView takes a closer look at five of our top picks for delivering the next potential treatments for the liver disease patient population, including Inventiva , NeuroBo Pharmaceuticals , and Better Therapeutics .

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

Retrieved on: 
Thursday, March 7, 2024
Therapy, FDA, Risk, Graft-versus-host disease, Safety, Drug development, CMC, Patient, Interview, Orphan, Cancer, PRISM, Pharmaceutical industry

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit.
  • Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease (GvHD) and previously received Orphan Drug Designation for LP-10 in 2023.
  • Dr. Kaufman remarked, “Orphan drug development can often be more profitable, entail lower risk and result in faster time to approval than non-orphan therapeutics.
  • Our goal is to deliver safe and effective treatments as quickly as possible to the patients who need them most,” said Dr. Kaufman.

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024
Rare disease, Therapy, Regenerative Medicine Advanced Therapy, FAP, Concha bullosa, Sulindac, Chemistry, Fast track (FDA), Muscular dystrophy, FDA, Sensation, News, Eflornithine, DMD, Prader–Willi syndrome, BLA, Chromosome, RDEB, PDUFA, Skin, Voyager, PRISM, Duchenne muscular dystrophy, Safety, Neurocrine Biosciences, Rare Disease Day, Genetics, Fatigue, Walking, PWS, Patient, DSM-IV codes, Medicine, Disease, Exosome, FA, CMC, Priority review, Pharmaceutical industry

All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders.

Key Points: 
  • All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders.
  • Today on Rare Disease Day, PRISM MarketView highlights emerging companies working to deliver life changing treatments for those living with rare diseases.
  • RDEB is a severe rare disease characterized by extremely fragile, and extensive blistering and wounds.
  • Capricor is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, February 29, 2024
Therapy, Atypical hemolytic uremic syndrome, Chelsea Handler, Fabry disease, Respiratory disease, EMA, Injection, Research, CRISPR, Cystic fibrosis, FDA, Partnership, Inflammation, Retinitis pigmentosa, Security (finance), Overalls, Biopsy, Șaeș, PRISM, Conference, Cash, Diabetic retinopathy, Geographic atrophy, Astellas Pharma, CFTR, CNS, PRIME, AMD, Choroideremia, Patient, Safety, Clinical trial, Angiogenesis, VG, DME, AAV, Vaccine

We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.

Key Points: 
  • We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.
  • R&D Expenses: Research and development expenses were $97.1 million for 2023, as compared to $80.3 million for 2022.
  • G&A Expenses: General and administrative expenses were $36.5 million for 2023, as compared to $32.9 million for 2022.
  • Net Loss: Net loss was $100.8 million for 2023, as compared to net loss of $107.5 million for 2022.

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Retrieved on: 
Wednesday, February 28, 2024
Research, HLA, Nivolumab, Sale, Skin, PRISM, PR, SME, Commercial, PIWIL1, Neoplasm, Research and development, CTA, Melanoma, BMY, HBV, Progression-free survival, Treatment, GMP, Cancer, Bristol Myers Squibb, Convertible, APC, Security (finance), Congress, Circulating tumor DNA, DNA, Immune system, Lung cancer, Total, ESMO, Conference, Safety, Ovary, RECIST, Infection, Oncology, IND, Mum, Conference call, PFS, Note, Annual report, Pro forma, PRAME, Event, Patient, TCR, HIV, Pharmaceutical industry

Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.

Key Points: 
  • Selling, general and administrative (SG&A) expenses for the year 2023 were $144.5 million, compared to $123.1 million for the year 2022.
  • The fourth quarter basic and diluted loss per share was $0.40, compared to $0.64 for the fourth quarter of 2022.
  • Topline data from the Phase 2 portion of the trial is expected to be available by the fourth quarter of 2024.
  • Immunocore will host a conference call today, February 28, 2024 at 8:00 A.M. ET/ 1:00 PM GMT, to discuss the fourth quarter and full year 2023 financial results and provide a business update.

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

Retrieved on: 
Monday, February 26, 2024
Matuszewski, Interview, Regenerative medicine, PRISM

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with BioStem Technologies ' CEO, Jason Matuszewski, discussing the company's strategic focus on revolutionizing the wound care market through innovative regenerative medicine solutions.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with BioStem Technologies ' CEO, Jason Matuszewski, discussing the company's strategic focus on revolutionizing the wound care market through innovative regenerative medicine solutions.
  • BioStem Technologies, a frontrunner in regenerative medicine, is dedicated to leveraging the healing properties of placental-derived allografts to enhance wound care.
  • The company stands out for its use of the patented BioRetain® process, which preserves the integrity of perinatal tissues, differentiating BioStem's products from competitors.
  • "We’re excited about the trial and believe it will provide invaluable real-world support for healthcare professionals," Matuszewski commented, emphasizing the company's dedication to delivering evidence-based solutions for chronic wound care.

Beroe introduces on-demand geopolitical risk analysis through PRISM enabling C-Suite to protect against ongoing supply chain disruptions

Retrieved on: 
Wednesday, March 6, 2024
Intelligence, Research, ESG, PRISM, Risk, CFOS, CONFIG.SYS, Software as a service, Geopolitics, Partnership, Retail

RALEIGH, N.C. and NEW YORK, March 6, 2024 /PRNewswire/ -- Beroe, the provider of a SaaS procurement intelligence and analytics platform used by over 80% of Fortune 500 companies, today announced a strategic partnership with PRISM, the global geopolitical and macro risk advisory service. Through this partnership, Beroe's customers will benefit from integrated alerts, reports and insights generated by PRISM's political risk experts into Beroe LiVE.Ai, its AI-Powered Procurement Intelligence Platform.

Key Points: 
  • Through this partnership, Beroe's customers will benefit from integrated alerts, reports and insights generated by PRISM's political risk experts into Beroe LiVE.Ai, its AI-Powered Procurement Intelligence Platform.
  • All Beroe LiVE.Ai users will immediately have access to top-level PRISM insights, with additional in-depth analysis available for an additional charge.
  • Access to timely, accurate and insightful intelligence is critical to successfully plan and build a resilient supply chain.
  • PRISM provides tailored research, data, analysis, and expertise, helping senior executives and their teams make strategic decisions in high stakes environments.

Beroe introduces on-demand geopolitical risk analysis through PRISM enabling C-Suite to protect against ongoing supply chain disruptions

Retrieved on: 
Wednesday, March 6, 2024
Intelligence, Research, ESG, PRISM, Risk, CFOS, CONFIG.SYS, Software as a service, Geopolitics, Partnership, Retail

RALEIGH, N.C. and NEW YORK, March 6, 2024 /PRNewswire/ -- Beroe, the provider of a SaaS procurement intelligence and analytics platform used by over 80% of Fortune 500 companies, today announced a strategic partnership with PRISM, the global geopolitical and macro risk advisory service. Through this partnership, Beroe's customers will benefit from integrated alerts, reports and insights generated by PRISM's political risk experts into Beroe LiVE.Ai, its AI-Powered Procurement Intelligence Platform.

Key Points: 
  • Through this partnership, Beroe's customers will benefit from integrated alerts, reports and insights generated by PRISM's political risk experts into Beroe LiVE.Ai, its AI-Powered Procurement Intelligence Platform.
  • All Beroe LiVE.Ai users will immediately have access to top-level PRISM insights, with additional in-depth analysis available for an additional charge.
  • Access to timely, accurate and insightful intelligence is critical to successfully plan and build a resilient supply chain.
  • PRISM provides tailored research, data, analysis, and expertise, helping senior executives and their teams make strategic decisions in high stakes environments.

Enverus Instant Analyst™ technology added to its AI-powered product portfolio

Retrieved on: 
Tuesday, February 20, 2024
Engineering, Collection, Amazon Web Services, Intelligence, Research, PRISM, Synthetic media, Software as a service, Automation, Energy, Knowledge, Hallucination, ExxonMobil, Interview, Instant, AWS

AUSTIN, Texas, Feb. 20, 2024 /PRNewswire/ -- Enverus, the most trusted energy-dedicated SaaS company, today announced it has added Instant Analyst™ technology to its market-leading product portfolio. Built on nearly 30 years of artificial intelligence software implementation experience, the company leads the way in generative AI technology to unlock even more value for its customers.

Key Points: 
  • With Enverus Instant Analyst™ technology, users can simply type in questions like, "Can you summarize critical KPIs of the Exxon-Pioneer deal?"
  • Together with Enverus Fusion® technology, Instant Analyst™ technology will enable customers to get insights from their own data at previously impossible speeds.
  • The Enverus Instant Analyst™ is available today in the Enverus Intelligence Vault™ on a trial basis for a select group of Enverus customers with access to Enverus Intelligence®.
  • Members of the media should contact Jon Haubert for a demonstration of Enverus Instant Analyst™ technology or to schedule an interview with one of Enverus' expert analysts.